Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

The aim of this updated guideline is to provide comprehensive and timely evidence-based
recommendations on the prevention of future stroke among survivors of ischemic stroke or …

BACKGROUND Bleeding is a potential complication after neuraxial and peripheral nerve
blocks. The risk is increased in patients on antiplatelet and anticoagulant drugs. This joint …

Background: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …

Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …

Objectives The aim of this study was to examine the effect of CYP2C19 genotype on clinical
outcomes in patients with coronary artery disease (CAD) who predominantly underwent …